Company performance
Add to research
Current Price
as of Jun 18, 2025$0.74
P/E Ratio
N/A
Market Cap
$29.05M
Description
Add to research
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Metrics
Add to research
Overview
- HQJersey City, NJ
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerSCYX
- Price$0.7445-0.73%
Trading Information
- Market cap$29.05M
- Float95.24%
- Average Daily Volume (1m)184,456
- Average Daily Volume (3m)129,234
- EPS-$0.58
Company
- Revenue$2.63M
- Rev growth (1yr)-81.28%
- Net income-$5.39M
- Gross marginN/A
- EBITDA margin-3,350.19%
- EBITDA-$8.61M
- EV$8.51M
- EV/Revenue3.24
- P/EN/A
- P/S13.99
- P/B0.57
- Debt/Equity4.92
Documents
Add to research
SEC Filings
Factset Street Account